Roche Holdings Ltd ADR (RHHBY)

$57.12 +0.37 (0.65%)
Market Cap 361.53B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.28
Profit Margin 13.27%
Debt to Equity Ratio 1.00
Volume 2,366,500
Avg Vol 2,629,514
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 96%
Beta 0.44
Analysts Sell
Price Target $52.12

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
free2dream
free2dream Feb. 2 at 2:53 PM
$SRPT $RHHBY would be stupid not to act. They spent $1B just to help develop elevidys, niow they can have the entire company for $2B . Pure insanity. Reminds me of early Aids days, no cure but Sarepta can improve the childrens lives. Market is completely ignoring that. 400M quarter coming up and the market prices sarepta at $2B market cap is absolutely IDIOTIC.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Feb. 2 at 1:48 PM
$ALT Watch out $LLY $NVO $RHHBY and $MDGL Looks like a best in class GLP1 for obesity/MASH is coming
0 · Reply
scotttrader213
scotttrader213 Feb. 2 at 1:02 PM
$RHHBY Long-term investors seeking large cap healthcare exposure • Dividend income + defensive positioning in uncertain markets • Exposure to global pharma R&D and diagnostic technologies
0 · Reply
scotttrader213
scotttrader213 Feb. 2 at 12:34 PM
$RHHBY one of the best pharma CO’s and stocks to own in bio tech sector. 12-15 month target 65-70 pa
0 · Reply
scotttrader213
scotttrader213 Feb. 2 at 12:27 PM
$RHHBY pipeline, especially in obesity and cardiovascular, positions it as a potential third major player in the GLP-1 market.
0 · Reply
free2dream
free2dream Feb. 1 at 10:38 PM
$SRPT $RHHBY Sales in the International region rose by 14%, led by Phesgo, Xofluza (influenza), Hemlibra, Vabysmo, Elevidys (Duchenne muscular dystrophy) and Polivy. In China, sales rose by 10%, driven by the uptake of Phesgo due to the inclusion in the government drug reimbursement list, strong sales of Xofluza and the continued roll-out of Vabysmo and Polivy.
0 · Reply
scotttrader213
scotttrader213 Jan. 31 at 11:18 PM
$RHHBY slow and steady towards 60, as the 50 and 200 MDA seem stronger! When it hit 40, I started buying realizing there is lots more to come. BTFD on this one
0 · Reply
scotttrader213
scotttrader213 Jan. 31 at 4:16 PM
$PFE $MRK $NVO $LLY $RHHBY Yesterday, TrumpRx was supposed to launch, it didn’t. No time table set as to when. So much for caring abt affordability when it comes to Americans and prescription drugs.
1 · Reply
scotttrader213
scotttrader213 Jan. 30 at 7:58 PM
$RHHBY nearing its 52 week high, once it pops through that it’s off to 60
0 · Reply
scotttrader213
scotttrader213 Jan. 30 at 7:26 PM
$RHHBY CT-388 – Phase III: A once-weekly injectable targeting dual GLP-1/GIP receptors, showing strong weight loss in Phase II and moving into Phase III soon. Roche expects this and other related candidates to launch by 2030.
0 · Reply
Latest News on RHHBY
No data available.
free2dream
free2dream Feb. 2 at 2:53 PM
$SRPT $RHHBY would be stupid not to act. They spent $1B just to help develop elevidys, niow they can have the entire company for $2B . Pure insanity. Reminds me of early Aids days, no cure but Sarepta can improve the childrens lives. Market is completely ignoring that. 400M quarter coming up and the market prices sarepta at $2B market cap is absolutely IDIOTIC.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Feb. 2 at 1:48 PM
$ALT Watch out $LLY $NVO $RHHBY and $MDGL Looks like a best in class GLP1 for obesity/MASH is coming
0 · Reply
scotttrader213
scotttrader213 Feb. 2 at 1:02 PM
$RHHBY Long-term investors seeking large cap healthcare exposure • Dividend income + defensive positioning in uncertain markets • Exposure to global pharma R&D and diagnostic technologies
0 · Reply
scotttrader213
scotttrader213 Feb. 2 at 12:34 PM
$RHHBY one of the best pharma CO’s and stocks to own in bio tech sector. 12-15 month target 65-70 pa
0 · Reply
scotttrader213
scotttrader213 Feb. 2 at 12:27 PM
$RHHBY pipeline, especially in obesity and cardiovascular, positions it as a potential third major player in the GLP-1 market.
0 · Reply
free2dream
free2dream Feb. 1 at 10:38 PM
$SRPT $RHHBY Sales in the International region rose by 14%, led by Phesgo, Xofluza (influenza), Hemlibra, Vabysmo, Elevidys (Duchenne muscular dystrophy) and Polivy. In China, sales rose by 10%, driven by the uptake of Phesgo due to the inclusion in the government drug reimbursement list, strong sales of Xofluza and the continued roll-out of Vabysmo and Polivy.
0 · Reply
scotttrader213
scotttrader213 Jan. 31 at 11:18 PM
$RHHBY slow and steady towards 60, as the 50 and 200 MDA seem stronger! When it hit 40, I started buying realizing there is lots more to come. BTFD on this one
0 · Reply
scotttrader213
scotttrader213 Jan. 31 at 4:16 PM
$PFE $MRK $NVO $LLY $RHHBY Yesterday, TrumpRx was supposed to launch, it didn’t. No time table set as to when. So much for caring abt affordability when it comes to Americans and prescription drugs.
1 · Reply
scotttrader213
scotttrader213 Jan. 30 at 7:58 PM
$RHHBY nearing its 52 week high, once it pops through that it’s off to 60
0 · Reply
scotttrader213
scotttrader213 Jan. 30 at 7:26 PM
$RHHBY CT-388 – Phase III: A once-weekly injectable targeting dual GLP-1/GIP receptors, showing strong weight loss in Phase II and moving into Phase III soon. Roche expects this and other related candidates to launch by 2030.
0 · Reply
scotttrader213
scotttrader213 Jan. 30 at 7:20 PM
$RHHBY huge pipeline and achieving all goals! Great buying opportunity long term!
0 · Reply
Initiator1
Initiator1 Jan. 30 at 5:29 PM
$RHHBY $SRPT Yes and maybe they should. But seems like investors are in for pain for a bit longer. The stock has been refusing to move.
1 · Reply
free2dream
free2dream Jan. 30 at 5:12 PM
$SRPT I agree $RHHBY should buy it while this cheap at $2B . However even at 500% premium the shareholders would probably reject it. The value is around $20B trading at $2B . Time will tell.
0 · Reply
TheMach99
TheMach99 Jan. 30 at 4:55 PM
$TGTX $RHHBY yup good points
0 · Reply
Biocreeper
Biocreeper Jan. 30 at 3:39 PM
$TGTX Did anyone catch the Roche ($RHHBY) ER? A few key takeaways relevant to Briumvi: 1. BTK Focus: They dedicated an entire slide to Fenebrutinib. 2. Liver Safety: Roche confirmed a case of Hy's Law in the FENhance 1 trial (the other case involved alcohol). Critical note: In the Tolebrutinib CRL, the FDA stated a single Hy's Law case is enough to deny approval if safer alternatives exist. 3. Revenue Read-through: Roche projects peak Ocrevus sales of $9B by 2029. This implies significant runway for Briumvi to capture market share. 4. IV vs. SC: They claim naive patients are adopting SC (Subcutaneous), but didn't break out the split. My projections suggest their IV growth is flat—they are likely just churning relapsing patients into SC rather than gaining net new share. 5. Oral MS Skepticism: Analysts noted that no oral MS drug approved post-CD20s has hit $1B in sales. Skepticism on Fenebrutinib revenue potential remains high.
4 · Reply
DmcMouse
DmcMouse Jan. 29 at 9:21 PM
$LMDX $RHHBY Roche diagnostics are up ~13% after Roche took over LumiraDx. Let’s be honest. Alere — older, lower-tech point-of-care tests — sold for $5.8 BILLION. LumiraDx — newer, better tech, FDA-cleared, global footprint, full workforce and pipeline — was sold for $350 MILLION (assets only). Roche’s share price was in the mid-$40S around the time of the LumiraDx deal and now trades around $50–$55. The market clearly sees value. Roche is benefiting. Diagnostics are growing. Shareholders got nothing. That leaves only two explanations: Either there is still a late resolution coming for shareholders, or we were flat-out ripped off
0 · Reply
clan
clan Jan. 29 at 5:03 AM
$NVS $ABBV $RHHBY Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No shooting up at meals! ❤️
0 · Reply
Quantumup
Quantumup Jan. 28 at 4:27 PM
Barclays assumed coverage of $PTCT ⬆️to Overweight-$119 from EW-$68 after initiating coverage of 12 biotech stocks and assuming coverage of 11, with a positive view of the industry. $BMRN $OTSKY RLFTY SYBX $QURE $RHHBY WVE TEVA Barclays says that it likes the setup for the group in 2026—many biotech stocks remain undervalued—expects continued M&A, strong underlying fundamentals, and less of a focus on drug pricing to act as significant tailwinds. Barclays additionally said, We think PKU could be >$2B at peak. We think PKU remains underappreciated and see Sephience beating in 2026 and beyond. Huntington's Disease (HD) could be meaningful long term and we view regulatory updates as potential upside drivers this year given low expectations.
0 · Reply
ZacksResearch
ZacksResearch Jan. 28 at 2:33 PM
$RHHBY’s obesity drug shows promise — could it shake up the market? CT-388 delivered a 22.5% placebo-adjusted weight reduction at 48 weeks at the highest tested dose, with 95.7% of patients on the 24 mg dose achieving significant weight loss and strong metabolic benefits. Shares have soared 40.6% in six months. Discover the full potential here 👉 https://www.zacks.com/stock/news/2824194/roche-reports-upbeat-efficacy-data-from-phase-ii-obesity-study?cid=sm-stocktwits-2-2824194-body-30650&ADID=SYND_STOCKTWITS_TWEET_2_2824194_BODY_30650
0 · Reply
ZacksResearch
ZacksResearch Jan. 28 at 1:19 PM
Roche’s obesity pipeline just flashed green —this could be a big deal. $RHHBY reported encouraging Phase II results as CT-388 delivered strong, sustained weight loss and metabolic benefits in adults with obesity or overweight. See the full efficacy breakdown and why it matters 👉 https://www.zacks.com/stock/news/2824194/roche-reports-upbeat-efficacy-data-from-phase-ii-obesity-study?cid=sm-stocktwits-2-2824194-teaser-30617&ADID=SYND_STOCKTWITS_TWEET_2_2824194_TEASER_30617
0 · Reply
4ENTRADES
4ENTRADES Jan. 28 at 6:05 AM
$LMDX if $RHHBY pays us ,I’ll invest $1MILLION into them.
0 · Reply
Coyote_7
Coyote_7 Jan. 27 at 10:10 PM
$CYDY $MRK $GSK $RHHBY ICIs treat cancers and can now be combined with Leronlimab. Longs, our time is coming!! 🔥 Prime-and-Pair Agent to unlock market share for years to come!! "These Leronlimab early-phase clinical trials were started pre-pandemic, when immune checkpoint inhibitors (“ICIs”) were still an emerging option in advanced triple-negative breast cancer,” said Dr. Milana V. Dolezal. “In this pooled analysis, we see sustained clinical benefit over five years later,..."
0 · Reply